Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to
achieve durable responses in first remission or in the relapsed or refractory settings …

Patients with rituximab-refractory follicular lymphoma (FL) have limited options. Before the
rituximab era, autologous stem cell transplant (ASCT) was shown to improve outcomes in …

High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
therapeutic option for patients with relapsed follicular lymphoma (FL). The clinical …

In advanced follicular lymphoma (FL), autologous stem cell transplant (ASCT) has been
studied extensively in an attempt to prolong remission duration and, possibly, achieve …

PURPOSE: High dose chemotherapy followed by ASCT is commonly used in responding
patients with FL as consolidation treatment in first relapse. Recently, rituximab maintenance …

High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT)
has contributed to modify the natural history of follicular lymphoma (FL); however, an overall …

Purpose The treatment of patients with follicular lymphoma has changed with the
introduction of high-dose therapy (HDT) with autologous stem-cell transplant then with …

Published studies have provided conflicting results regarding the curative potential of high
dose chemotherapy and autologous stem cell transplant (HDT/ASCT) for follicular …

Background: There is no standard therapeutic approach for patients (pts) with relapsed
advanced stage follicular lymphoma (FL). The impact of high-dose therapy followed by …

Three sequential phase II trials were conducted with different immunotherapy approaches to
enhance the outcome of autologous transplant (high-dose therapy and autologous stem cell …